Search

Your search keyword '"Kramer, G."' showing total 321 results

Search Constraints

Start Over You searched for: Author "Kramer, G." Remove constraint Author: "Kramer, G." Database OAIster Remove constraint Database: OAIster
321 results on '"Kramer, G."'

Search Results

1. Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022

2. Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022

3. Pembrolizumab Plus Olaparib for Patients With Previously Treated and Biomarker-Unselected Metastatic Castration-Resistant Prostate Cancer: The Randomized, Open-Label, Phase III KEYLYNK-010 Trial

4. Addition of FFRct in the diagnostic pathway of patients with stable chest pain to reduce unnecessary invasive coronary angiography (FUSION) Rationale and design for the multicentre, randomised, controlled FUSION trial

5. DIII-D research advancing the physics basis for optimizing the tokamak approach to fusion energy

6. DIII-D research advancing the physics basis for optimizing the tokamak approach to fusion energy

7. DIII-D research advancing the physics basis for optimizing the tokamak approach to fusion energy

8. DIII-D research advancing the physics basis for optimizing the tokamak approach to fusion energy

9. Overview of the SPARC tokamak

10. Breast and Prostate Cancer Risks for Male BRCA1 and BRCA2 Pathogenic Variant Carriers Using Polygenic Risk Scores.

11. Breast and Prostate Cancer Risks for Male BRCA1 and BRCA2 Pathogenic Variant Carriers Using Polygenic Risk Scores.

14. Breast and Prostate Cancer Risks for Male BRCA1 and BRCA2 Pathogenic Variant Carriers Using Polygenic Risk Scores

15. Baseline neutrophil-to-lymphocyte ratio as a predictive and prognostic biomarker in patients with metastatic castration-resistant prostate cancer treated with cabazitaxel versus abiraterone or enzalutamide in the CARD study.

18. Cross sections of inclusive $\psi(2S)$ and $X(3872)$ production from $b$-hadron decays in $pp$ collisions and comparison with ATLAS and CMS data

19. Baseline neutrophil-to-lymphocyte ratio as a predictive and prognostic biomarker in patients with metastatic castration-resistant prostate cancer treated with cabazitaxel versus abiraterone or enzalutamide in the CARD study

20. Our reaction on the comment of Yosiko Myoken et al. on ‘The effect of using a mobile application (“WhiteTeeth”) on improving oral hygiene: A Randomized Controlled Trial by Scheerman et al.’

21. Radium-223 Within the Evolving Treatment Options for Metastatic Castration-resistant Prostate Cancer: Recommendations from a European Expert Working Group

22. Mapping carbon of the Dutch industry today and how this can evolve towards circularity.

23. Association of genomic domains in BRCA1 and BRCA2 with prostate cancer risk and aggressiveness.

24. Mapping carbon of the Dutch industry today and how this can evolve towards circularity.

25. Association of genomic domains in BRCA1 and BRCA2 with prostate cancer risk and aggressiveness.

26. Association of Genomic Domains in BRCA1 and BRCA2 with Prostate Cancer Risk and Aggressiveness

27. Radium-223 Within the Evolving Treatment Options for Metastatic Castration-resistant Prostate Cancer: Recommendations from a European Expert Working Group

28. Radium-223 Within the Evolving Treatment Options for Metastatic Castration-resistant Prostate Cancer: Recommendations from a European Expert Working Group

29. $\Lambda_c^{\pm}$ production in pp collisions with a new fragmentation function

30. Mapping carbon of the Dutch industry today and how this can evolve towards circularity.

32. Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer

33. Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer

34. Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer

35. B-meson production in the general-mass variable-flavour-number scheme and LHC data

39. DIII-D research towards establishing the scientific basis for future fusion reactors

40. Quality of life in adult patients with epilepsy and their family members

41. Investment in the future electricity system - An agent-based modelling approach

42. b-Hadron production in the general-mass variable-flavour-number scheme and LHC data

43. $\Lambda_b^0$-baryon production in pp collisions in the general-mass variable-flavour-number scheme and comparison with CMS and LHCb data

44. Rate-distortion performance of lossy compressed sensing of sparse sources

45. Quality of life in adult patients with epilepsy and their family members

46. Investment in the future electricity system - An agent-based modelling approach

48. Kom in Actie! Jeugdbuurtprojecten Onderzocht

50. Prompt neutrinos from atmospheric charm in the general-mass variable-flavor-number scheme

Catalog

Books, media, physical & digital resources